Estimation of efficacy of Reduced form of Coenzyme Q10 (Ubiquinol) to fatigue

Estimation of efficacy of Reduced form of Coenzyme Q10 (Ubiquinol) to fatigue - Anti-fatigue effect of Reduced form of Coenzyme Q10

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021221

Enrollment

Registered

2016-03-01

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Reduced form of Coenzyme Q10 ( 100mg/day), 3months, 25 healthy person. Reduced form of Coenzyme Q10(150mg/day), 3months, 25 healthy person. Placebo, 3months, 25 healthy person

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.age:over 20 y.o 2.healthy person

Exclusion criteria

Exclusion criteria: 1.Under medication. 2.Take coenzyme Q10 supplement. 3.Take medicine that might impact the outcome measures. 4.Patient of serious disease such as diabetes, live disease, renal disease, heart disease, mental disease, disease to become the motive of fatigue, cardiovascular, nerve, allergy, insomnia. 5.Pregnant and women who wish to pregnant in this study period. 6.alcholism 7.Doctor did not allow to entry to this study. 8.Entry another clinical study which ongoing or performed within 1 month.

Design outcomes

Primary

Measure	Time frame
Autonomic nervous system, Oxidation stress, Antioxidant activity, Cognitive function, Condition of sleep, VAS(fatigue), These items will be determined at 0, 4, 8 and 12 weeks.	—

Secondary

Measure	Time frame
Physical active mass	—

Countries

Japan

Contacts

Public ContactKenji Fujii

KANEKA CORPORATION QOL Division

Kenji.Fujii@kaneka.co.jp03-5574-8112

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026